Short Interest in Franklin Genomic Advancements ETF (BATS:HELX) Declines By 37.8%

Franklin Genomic Advancements ETF (BATS:HELX) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 2,561 shares, a decrease of 37.8% from the July 15th total of 4,118 shares. Approximately 0.6% of the shares of the stock are sold short. Based on an average daily volume of 4,032 shares, the short-interest ratio is presently 0.6 days.

Franklin Genomic Advancements ETF Stock Performance

Shares of BATS HELX opened at $41.14 on Tuesday. The stock has a fifty day moving average price of $39.02 and a two-hundred day moving average price of $35.73. The firm has a market cap of $16.46 million, a P/E ratio of 26.71 and a beta of 1.05. Franklin Genomic Advancements ETF has a 1 year low of $29.26 and a 1 year high of $41.76.

Institutional Trading of Franklin Genomic Advancements ETF

Institutional investors have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new position in Franklin Genomic Advancements ETF during the fourth quarter valued at about $39,000. Raymond James Financial Inc. bought a new stake in Franklin Genomic Advancements ETF in the second quarter worth about $42,000. Osaic Holdings Inc. lifted its holdings in Franklin Genomic Advancements ETF by 19.1% in the 2nd quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after acquiring an additional 502 shares during the last quarter. Finally, LPL Financial LLC lifted its holdings in Franklin Genomic Advancements ETF by 22.4% in the 4th quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock valued at $404,000 after acquiring an additional 2,037 shares during the last quarter.

About Franklin Genomic Advancements ETF

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.